ARTV.US Artiva Biotherapeutics, Inc. Common Stock

Healthcare Biotechnology USA Stocks
4.01 USD
Close of Nov 13, 2026
2.96 14.53
Market cap
USD 198M
P/E
-
P/B
0.61x
ROE
-32.2%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is ARTV.US undervalued?

Graham number

The Graham number of Artiva Biotherapeutics, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Artiva Biotherapeutics, Inc. Common Stock fundamental analysis

No fundamental analysis for Artiva Biotherapeutics, Inc. Common Stock yet.

Artiva Biotherapeutics, Inc. Common Stock stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Artiva Biotherapeutics, Inc. Common Stock

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibo…

Full company profile